Programmed cell death-1 blockade in recurrent disseminated Ewing sarcoma.
Ewing sarcoma (EWS) is a malignant tumour of bone and soft tissue, and although many patients are cured with conventional multimodal therapy, those with recurrent or metastatic disease have a poor prognosis. Genomic instability and programmed cell death ligand-1 (PD-L1) expression have been identified in EWS, providing a rationale for treatment with agents that block the programmed cell death-1 (PD-1) receptor.



In this report, we describe a heavily pre-treated patient with recurrent metastatic EWS who achieved a clinical and radiological remission with PD-1 blockade.



To our knowledge, this is the first reported case demonstrating efficacy of PD-1 blockade in EWS. This warrants further investigation in particular given the poor prognosis in patients with recurrent or metastatic disease.
Royal Prince Alfred Hospital, Camperdown, NSW, Australia.
Georgia J B
GJ
McCaughan
Royal Prince Alfred Hospital, Camperdown, NSW, Australia.|Sydney Medical School, University of Sydney, Sydney, NSW, Australia.
Michael J
MJ
Fulham
Royal Prince Alfred Hospital, Camperdown, NSW, Australia.
Annabelle
A
Mahar
Royal Prince Alfred Hospital, Camperdown, NSW, Australia.|Specialist Magnetic Resonance Imaging, Newton, NSW, Australia.
Judy
J
Soper
Sydney Medical School, University of Sydney, Sydney, NSW, Australia.|Chris O'Brien Lifehouse, 119-143 Missenden Road, Camperdown, NSW, 2050, Australia.
Angela M
AM
Hong
Royal Prince Alfred Hospital, Camperdown, NSW, Australia.
Paul D
PD
Stalley
Sydney Medical School, University of Sydney, Sydney, NSW, Australia.|Chris O'Brien Lifehouse, 119-143 Missenden Road, Camperdown, NSW, 2050, Australia.
Martin H N
MH
Tattersall
Sydney Medical School, University of Sydney, Sydney, NSW, Australia. vivek.bhadri@lh.org.au.|Chris O'Brien Lifehouse, 119-143 Missenden Road, Camperdown, NSW, 2050, Australia. vivek.bhadri@lh.org.au.
Vivek A
VA
Bhadri
D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage / Q000494:pharmacology; D000074322:Antineoplastic Agents, Immunological / Q000008:administration & dosage / Q000494:pharmacology; D006801:Humans; D008297:Male; D009362:Neoplasm Metastasis; D061026:Programmed Cell Death 1 Receptor / Q000037:antagonists & inhibitors*; D012008:Recurrence; D012512:Sarcoma, Ewing / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy; D016896:Treatment Outcome; D055815:Young Adult
D061067:Antibodies, Monoclonal, Humanized; D000074322:Antineoplastic Agents, Immunological; C105992:PDCD1 protein, human; D061026:Programmed Cell Death 1 Receptor; C582435:pembrolizumab
Anti-programmed cell death-1 antibody; Case report; Ewing sarcoma; Immunotherapy